A U.S. clinical trial shows that a smoking cessation vaccine is effective

U.Sresearchers released the results of a clinical trial on the 7th, said a smoking cessation vaccine called "NicVAX" can more than double the number of quittersAmong them, the proportion of smokers who received high-dose smoking cessation vaccinations and those who received lower-dose vaccinations quit smoking for one year was 16% and 14%, respectivelyOnly 6% of smokers who received a placebo were able to hold on for 1
2
months without a cigaretteDouble the numberthe smoking cessation vaccine was developed by Nabi Biopharmaceuticals incin FloridaResearchers led by Stephen Leonard, Ph.D., University of Nebraska, conducted a clinical trialThe results were presented Wednesday at the AmericanHeartSociety meetingThe researchers recruited 301 volunteers from different cities, including Minneapolis
,Boston, New York These volunteers have a long history of smoking Over a six-month , researchers gave 2
01 of them the smoking cessation vaccine, and the remaining 100 with the same dose of placebo To minimize the of the results from the effects of psychological , the researchers did not tell volunteers who had been vaccinated against smoking cessation The results of the follow-up study over the next year showed that 16 percent of volunteers who received high-dose smoking cessation vaccinations were able to quit smoking for 1
2
months , and 14 percent of volunteers who received low-dose smoking cessation vaccines were able to stop smoking for at least one year This proportion was only 6 per cent of those given placebo injections Among them, the volunteers who received the most antibodies after receiving the vaccine had the longest time to quit smoking The volunteers who did not quit smoked also smoked 10 cigarettes a day from 20 after the vaccination Researchers at the antibody say NicVAX helps people quit smoking because it encourages the body's immune system to produce antibodies to nicotine When people smoke, nicotine in tobacco is usually transmitted through the blood to the brain, stimulating nerve receptors to produce pleasure, which in turn leads to addiction But because the nicotine molecule is small, the immune system cannot recognize it and is unable to resist it The NicVAX vaccine effectively captures nicotine molecules in the blood and enables the immune system to produce antibodies that recognize and block nicotine molecules entering the brain, preventing the body from experiencing the intoxication of smoking The study also says that because some nicotine may also "avoid" the "hunt" of the smoking cessation vaccine and enter the brain, smokers may still re-inhale if they are not strong enough " This development is critical to smoking cessation research and will have a significant impact on our treatment of nicotine addicts," Leonard said in a statement "
alternative choice
according to the American Heart Society, there are 1.3 billion people smoking globally, and the number of smokers in the United States reached 46 million Smoking has been shown to be a major cause of cancer and heart disease " Getting people to quit smoking could be at the top of the list of improving public health," said Sydney Smith, former president of the American Heart Association "
fact, people are not without recognition of the dangers of smoking In the United States, 40 percent of smokers try to quit smoking very hard each year, but less than 5 percent are able to quit smoking altogether Experts say one reason may be that traditional smoking cessation methods such as chewing gum , taking medication
, applying ointment often focus on how to replace nicotine These methods may not necessarily work for people who are less of willpower or have older smokers Therefore, for these people, the NicVAX vaccine for the human body's dependence on nicotine may be a good choice Given the unique advantages of the NicVAX vaccine, the U.S Food and Drug Administration has prioritized its efficacy assessment (
Shanshan)